Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;149(1):531-540.
doi: 10.1007/s00432-022-04485-1. Epub 2022 Nov 19.

Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis

Meiya He  1 , Nan Jiang  1 , Xiaoxv Yin  1 , Anhui Xu  2 , Ketao Mu  3
Affiliations

Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a systematic review and pooled analysis

Meiya He et al. J Cancer Res Clin Oncol. 2023 Jan.

Abstract

Purpose: Patients with unresectable intrahepatic cholangiocarcinoma (ICC) have poor survival. Conventional transarterial chemoembolization (c-TACE) and drug-eluting beads transarterial chemoembolization (DEB-TACE) are two treatment options for ICC, and this systematic review describes the efficacy of each of these modalities for unresectable ICC to guide clinical practice.

Methods: A literature search was performed in PubMed, Web of Science, and Embase databases regarding transhepatic arterial chemoembolization for intrahepatic cholangiocarcinoma. The Newcastle-Ottawa quality assessment Scale (NOS) was used to assess the risk of bias. Tumor response, disease control, and 1-, 2-, 3-year overall survival rate were pooled for estimation.

Results: The number of initial search results was 1035, and 19 articles met the inclusion criteria for this study after the screening. A total of 23 study cohorts and 1091 patients were provided. The pooled objective response rate (ORR) for c-TACE and DEB-TACE treating ICC was 29.4% (95% CI 11.6-50.8%) and 51.2% (95% CI 30.6-71.7%), respectively; disease control rate (DCR) was 72.8% (95% CI 55.6-87.3%) and 88.7% (95% CI 78.8-96.2%), respectively. The pooled survival rate at 1 year, 2 year, and 3 year was 49.7% (95% CI 39.1-60.3%), 24.0% (95% CI 12.6-37.3%), and 23.5% (95% CI 11.1-38.7%) for c-TACE; 58.6% (95% CI 44.2-72.3%), 26.7% (95% CI 18.1-36.3%), and 16.2% (95% CI 6.0-29.4%) for DEB-TACE.

Conclusion: The descriptive analysis suggested that DEB-TACE treatment for ICC may have better tumor response and disease control rates than c-TACE treatment, but the impact on overall survival was not demonstrated significantly by DEB-TACE treatment.

Keywords: Bile ducts cancer; Chemotherapy; Interventional oncology; Intra-arterial therapies; Meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose. Neither the entire paper nor any part of its content has been submitted to any other journal.

Figures

Fig. 1
Fig. 1
PRISMA flowchart of selection of the studies included (ICC intrahepatic cholangiocarcinoma, c-TACE conventional transarterial chemoembolization, DEB-TACE drug-eluting beads transarterial chemoembolization)
Fig. 2
Fig. 2
Pooled ORR, DCR, and 1-, 2-, 3-year OS rate in c-TACE and DEB-TACE group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Aliberti C, Benea G, Tilli M et al (2008) Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 31(5):883–888. 10.1007/s00270-008-9336-2 - PubMed
    1. Aliberti C, Carandina R, Sarti D et al (2017) Chemoembolization with drug-eluting microspheres loaded with doxorubicin for the treatment of cholangiocarcinoma. Anticancer Res 37(4):1859–1863. 10.21873/anticanres.11522 - PubMed
    1. Aljiffry M, Abdulelah A, Walsh M et al (2009) Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208(1):134–147. 10.1016/j.jamcollsurg.2008.09.007 - PubMed
    1. Boehm LM, Jayakrishnan TT, Miura JT et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111(2):213–220. 10.1002/jso.23781 - PubMed
    1. Bzeizi KI, Arabi M, Jamshidi N et al (2021) Conventional transarterial chemoembolization versus drug-eluting beads in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Cancers. 10.3390/cancers13246172 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources